1. Home
  2. EPM vs ADCT Comparison

EPM vs ADCT Comparison

Compare EPM & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evolution Petroleum Corporation Inc.

EPM

Evolution Petroleum Corporation Inc.

N/A

Current Price

$3.49

Market Cap

152.7M

Sector

Energy

ML Signal

N/A

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

N/A

Current Price

$1.43

Market Cap

136.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPM
ADCT
Founded
2003
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.7M
136.1M
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
EPM
ADCT
Price
$3.49
$1.43
Analyst Decision
Strong Buy
Buy
Analyst Count
4
5
Target Price
★ $4.88
$3.33
AVG Volume (30 Days)
362.1K
★ 1.2M
Earning Date
11-10-2026
11-09-2026
Dividend Yield
★ 13.83%
N/A
EPS Growth
N/A
★ 30.86
EPS
★ N/A
N/A
Revenue
$43,229,621.00
★ $81,357,000.00
Revenue This Year
$6.78
N/A
Revenue Next Year
N/A
$25.89
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 14.85
52 Week Low
$3.19
$0.78
52 Week High
$4.99
$4.98

Technical Indicators

Market Signals
Indicator
EPM
ADCT
Relative Strength Index (RSI) 40.34 46.57
Support Level $3.40 $1.39
Resistance Level $3.85 $1.45
Average True Range (ATR) 0.15 0.17
MACD -0.04 -0.02
Stochastic Oscillator 33.41 5.43

Price Performance

Historical Comparison
EPM
ADCT

About EPM Evolution Petroleum Corporation Inc.

Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: